- Home
- CSTL vs TTI Comparison
CSTL vs TTI Comparison
Compare CSTL & TTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TTI
- Stock Information
- Founded
- CSTL 2007
- TTI 1981
- Country
- CSTL United States
- TTI United States
- Employees
- CSTL 784
- TTI N/A
- Industry
- CSTL Medical Specialities
- TTI Oil & Gas Production
- Sector
- CSTL Health Care
- TTI Energy
- Exchange
- CSTL Nasdaq
- TTI Nasdaq
- Market Cap
- CSTL 456.2M
- TTI 363.3M
- IPO Year
- CSTL 2019
- TTI 1990
- Fundamental
- Price
- CSTL $15.95
- TTI $2.68
- Analyst Decision
- CSTL Strong Buy
- TTI Strong Buy
- Analyst Count
- CSTL 6
- TTI 2
- Target Price
- CSTL $37.67
- TTI $5.25
- AVG Volume (30 Days)
- CSTL 527.3K
- TTI 1.2M
- Earning Date
- CSTL 05-05-2025
- TTI 04-29-2025
- Dividend Yield
- CSTL N/A
- TTI N/A
- EPS Growth
- CSTL N/A
- TTI 426.72
- EPS
- CSTL N/A
- TTI 0.84
- Revenue
- CSTL $347,083,000.00
- TTI $605,279,000.00
- Revenue This Year
- CSTL N/A
- TTI $2.67
- Revenue Next Year
- CSTL $1.80
- TTI $7.55
- P/E Ratio
- CSTL N/A
- TTI $3.05
- Revenue Growth
- CSTL 38.43
- TTI N/A
- 52 Week Low
- CSTL $15.45
- TTI $2.03
- 52 Week High
- CSTL $35.84
- TTI $5.12
- Technical
- Relative Strength Index (RSI)
- CSTL 33.63
- TTI 41.93
- Support Level
- CSTL $15.45
- TTI $2.68
- Resistance Level
- CSTL $16.43
- TTI $2.82
- Average True Range (ATR)
- CSTL 0.59
- TTI 0.12
- MACD
- CSTL 0.04
- TTI -0.02
- Stochastic Oscillator
- CSTL 15.93
- TTI 6.72
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.